Cutler Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Cutler Group’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200	Closed	-$1K	–	4473
2023 Q3	$1K	Buy	+200	New	+$1.17K	﹤0.01%	3687

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cutler Group's YMAB Position: Q4 2023 in Review

Cutler Group sold out of Y-mAbs Therapeutics (YMAB) in Q4 2023, closing a stake of 200 shares — an estimated $1K sold.

Cutler Group first reported a position in YMAB in Q3 2023 and held it in 1 quarter. The position peaked at $1K in Q3 2023. 94 funds tracked by Wall St. Rank hold YMAB as of Q4 2023.

Cutler Group reported no remaining Y-mAbs Therapeutics position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 200 Y-mAbs Therapeutics shares in Q4 2023, an estimated $1K.
Cutler Group first reported a position in Y-mAbs Therapeutics in Q3 2023 and held it in 1 quarter.
Cutler Group's Y-mAbs Therapeutics position peaked at $1K in Q3 2023.
94 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.